Sign up online today & collaborate
or click here to find out more
AstraZeneca today announced that Professor David Goldstein will join the Company in the consultative role of Chief Adviser, Genomics to lead its integrated genomics initiative, which was announced in April. This 10-year initiative will focus on the discovery of new targets and biomarkers linked to molecular mechanisms of disease across AstraZeneca’s main therapy areas.
Professor Goldstein will continue in his full-time role as Director of the Institute for Genomic Medicine, John E. Borne Professor and Professor of Genetics and Development at Columbia University Medical Center. He is renowned for his research on human genetic diversity, the genetics of disease and pharmacogenetics and will be responsible for driving the scientific progress of AstraZeneca’s genomics initiative, created to transform drug discovery and development across the entire research and development pipeline. AstraZeneca’s new Centre for Genomics Research is based in Cambridge, UK, with teams located across the company’s strategic R&D sites in the US, UK and Sweden.
Professor Goldstein said: “AstraZeneca has placed genomics at the centre of its strategy for researching and developing medicines that will change the lives of patients around the world. Having served as the Chair of the company’s genomics advisory panel since 2015, I’m now excited to take on this important role and lead the implementation of the panel’s recommendations. One of my first tasks is to establish a world-leading team to execute AstraZeneca’s ambitious genomics approach across its pipeline.”
Mene Pangalos, Executive Vice President, Innovative Medicines and Early Development and Global Business Development at AstraZeneca, said: “We’re delighted to welcome David to AstraZeneca at a very exciting time for our company and the rapidly evolving field of genomics. Our ambition is to develop life-changing treatments for patients and our genomics strategy is at the heart of this. David is a world-renowned expert in genomics, and his expertise will help to accelerate the integration of genomics across our entire research and development pipeline.”
Professor Goldstein received his PhD in biological sciences from Stanford University in 1994 and has previously held positions at University College London and Duke University, North Carolina. He has published over 250 papers in the field and is a recipient of the Royal Society Wolfson Research Merit Award.
Genomics is the study of the genome, which provides the full set of instructions needed to make every cell, tissue and organ in our bodies. In humans, the entire genome (more than three billion DNA base pairs) includes all of the genes that code for proteins and define our characteristics. Although most of the information in the genome is the same between individuals, there are small differences, which scientists believe can combine with environmental influences to cause diseases such as diabetes, asthma or cancer. Studying genome sequences across large populations allows us to develop innovative new treatments and target the right patients to the right medicines.
NOTES TO EDITORS
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory & Autoimmunity, Cardiovascular & Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
+44 203 749 5637
+44 203 749 5634
+1 302 885 2677